Safety and efficacy of adjuvant FOLFOX/FOLFIRI with versus without hepatic arterial infusion of floxuridine in patients following colorectal cancer liver metastasectomy (HARVEST trial): A randomized controlled trial

Eur J Cancer. 2025 Jan:214:115154. doi: 10.1016/j.ejca.2024.115154. Epub 2024 Nov 30.

Abstract

Background: Hepatic artery infusion (HAI) chemotherapy, particularly with floxuridine (FUDR), has previously shown effectiveness in improving recurrence-free survival (RFS) in colorectal cancer (CRC) patients with colorectal liver metastases (CRLM). Nonetheless, its adjuvant use alongside modern systemic chemotherapy remains unevaluated.

Patients and methods: The HARVEST trial is an open-label, randomized, controlled study conducted from May 2018 to August 2021. CRC patients with resectable primary tumors and CRLM were recruited and randomized to receive standard systemic chemotherapy only (non-HAI group) or in combination with HAI-FUDR (HAI group). However, due to a FUDR manufacturing shortage, the study was terminated early after enrolling 92 patients. The primary endpoint was the 3-year RFS rate, with secondary endpoints including overall survival (OS), liver-specific RFS, and adverse events.

Results: Of the 92 randomized patients, 77 were included in the modified intention-to-treat analysis. Three-year RFS rates were comparable between the HAI (N = 38) and non-HAI (N = 39) groups (31.4 % vs. 34.4 %; P = 0.28). However, improved 1-year RFS and a longer expected five-year OS were observed in the HAI group. While exploratory subgroup analysis suggested potential RFS benefits for patients with multiple liver metastases, RAS/BRAF mutations, and positive postoperative ctDNA methylation, multivariable analysis did not identify these as independent factors. Safety analysis showed comparable chemotherapy-related adverse events, except for a higher occurrence of ALT elevation in the HAI group.

Conclusions: While our study showed no significant difference in three-year RFS, adjuvant chemotherapy intensification with HAI-FUDR is feasible and may offer early benefits in RFS and long-term OS. Nonetheless, a larger sample size is needed for validation and identifying which patient subgroup might benefit from this regimen.

Trial registration: ClinicalTrials.gov: NCT03500874.

Keywords: Adjuvant chemotherapy; Colorectal cancer liver metastases; Hepatic arterial infusion; Overall survival; Recurrence-free survival.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols* / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
  • Camptothecin / administration & dosage
  • Camptothecin / analogs & derivatives
  • Camptothecin / therapeutic use
  • Chemotherapy, Adjuvant
  • Colorectal Neoplasms* / drug therapy
  • Colorectal Neoplasms* / pathology
  • Female
  • Floxuridine* / administration & dosage
  • Fluorouracil* / administration & dosage
  • Hepatic Artery*
  • Humans
  • Infusions, Intra-Arterial*
  • Leucovorin* / administration & dosage
  • Leucovorin* / therapeutic use
  • Liver Neoplasms* / drug therapy
  • Liver Neoplasms* / secondary
  • Male
  • Metastasectomy* / methods
  • Middle Aged
  • Organoplatinum Compounds / administration & dosage
  • Organoplatinum Compounds / therapeutic use

Substances

  • Floxuridine
  • Fluorouracil
  • Leucovorin
  • Camptothecin
  • Organoplatinum Compounds

Supplementary concepts

  • Folfox protocol
  • IFL protocol

Associated data

  • ClinicalTrials.gov/NCT03500874